

Middle East and Africa Drug Delivery Devices Market

Market Report | 2024-08-01 | 217 pages | Data Bridge Market Research

AVAILABLE LICENSES:

- Single User License \$3500.00
- Corporate Users License \$4200.00

Report description:

The Middle East and Africa drug delivery devices market is expected to reach USD 48.96 billion by 2031 from USD 26.41 billion in 2023, growing at a CAGR of 8.3% in the forecast period of 2024 to 2031.

Market Segmentation:

Middle East and Africa Drug Delivery Devices Market, By Product Type (Oral Drug Delivery, Injectable Drug Delivery, Topical Drug Delivery, Ophthalmic Drug Delivery, Nasal Drug Delivery, Pulmonary Drug Delivery, Transmucosal Drug Delivery, and Implantable Drug Delivery), End User (Hospitals, Home Healthcare, Clinics, Community Healthcare, and Others), Distribution Channel (Direct Tenders, Hospital Pharmacies, Pharmacy Stores, and Online Pharmacy), Country (South Africa, Egypt, Saudi Arabia, U.A.E., Israel, and rest of Middle East and Africa) - Industry Trends and Forecast to 2031

Overview of Middle East and Africa Drug Delivery Devices Market Dynamics:

Driver

- Rising prevalence of chronic disease and non-chronic disease

Restraint

- High costs of injectable drugs

Opportunity

- Rising acceptance of self-administering drug devices

Market Players:

The key market players operating in the Middle East and Africa drug delivery devices market are listed below:

- Johnson & Johnson Services, Inc.
- Novartis AG
- F.Hoffmann-La Roche Ltd
- Bayer AG
- Pfizer Inc.
- 3M
- AbbVie Inc.
- Amgen Inc.
- BD
- Elcam Medical

Scotts International. EU Vat number: PL 6772247784

- Gerresheimer AG
- GSK plc.
- Insulet Corporation
- Merck & Co., Inc.
- Sanofi
- West Pharmaceutical Services Inc.

Table of Contents:

- 1 INTRODUCTION 24
- 1.1 OBJECTIVES OF THE STUDY 24
- 1.2 MARKET DEFINITION 24
- 1.3 OVERVIEW OF THE MIDDLE EAST AND AFRICA DRUG DELIVERY DEVICES MARKET 24
- 1.4 CURRENCY AND PRICING 26
- 1.5 LIMITATIONS 26
- 1.6 MARKETS COVERED 26
- 2 MARKET SEGMENTATION 30
- 2.1 MARKETS COVERED 30
- 2.2 GEOGRAPHICAL SCOPE 31
- 2.3 YEARS CONSIDERED FOR THE STUDY 32
- 2.4 DBMR TRIPOD DATA VALIDATION MODEL 33
- 2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 36
- 2.6 MULTIVARIATE MODELLING 37
- 2.7 MARKET END USER COVERAGE GRID 38
- 2.8 PRODUCT TYPE LIFELINE CURVE 38
- 2.9 DBMR MARKET POSITION GRID 39
- 2.10 VENDOR SHARE ANALYSIS 40
- 2.11 SECONDARY SOURCES 41
- 2.12 ASSUMPTIONS 41
- 3 EXECUTIVE SUMMARY 42
- 4 PREMIUM INSIGHTS 47
- 4.1 PORTERS FIVE FORCES 48
- 4.2 PESTEL ANALYSIS 49
- 5 REGULATORY FRAMEWORK 50
- 6 MARKET OVERVIEW 51
- 6.1 DRIVERS 53
- 6.1.1 RISING PREVALENCE OF CHRONIC DISEASE AND NON-CHRONIC DISEASE 53
- 6.1.2 GROWTH IN THE DEVELOPMENT OF BIOLOGICS DRUGS DEVICES 53
- 6.1.3 INCREASING AWARENESS ABOUT DIAGNOSIS AND TREATMENT 55
- 6.1.4 INCREASED FOCUS ON PERSONALIZED MEDICINE AND DEVICES 55
- 6.2 RESTRAINTS 56
- 6.2.1 RISK OF NEEDLE-STICK INJURIES AND SIDE EFFECTS 56
- 6.2.2 HIGH COSTS OF INJECTABLE DRUGS 57
- 6.2.3 STRINGENT REGULATORY SCENARIO 58
- 6.3 OPPORTUNITIES 59
- 6.3.1 RISING ACCEPTANCE OF SELF-ADMINISTERING DRUG DEVICES 59

Scotts International. EU Vat number: PL 6772247784

- 6.3.2 RISING DEMAND FOR BIOSIMILAR AND GENERIC DRUGS 59
- 6.3.3 THERAPEUTIC ADVANCEMENTS IN THE FIELD OF DRUG DELIVERY 60
- 6.4 CHALLENGES 60
- 6.4.1 SIDE EFFECTS OF DRUG DELIVERY SYSTEMS 60
- 6.4.2 INCREASE IN THE NUMBER OF ALTERNATIVES OF DRUG DELIVERY 61
- 7 MIDDLE EAST AND AFRICA DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE 62
- 7.1 OVERVIEW 63
- 7.2 ORAL DRUG DELIVERY 66
- 7.2.1 SOLID ORAL DRUGS 67
- 7.2.1.1 TABLETS 67
- 7.2.1.2 CAPSULES 67
- 7.2.1.3 PILLS 67
- 7.2.1.4 POWDERS 67
- 7.2.2 LIQUID ORAL DRUGS 68
- 7.2.2.1 SYRUPS 68
- 7.2.2.2 SOLUTIONS 68
- 7.2.3 SEMI SOLID ORAL DRUGS 68
- 7.2.3.1 GELS 68
- 7.2.3.2 EMULSIONS 68
- 7.2.3.3 ELIXIRS 69
- 7.3 INJECTABLE DRUG DELIVERY 69
- 7.3.1 INJECTABLE DRUG DELIVERY FORMULATIONS 70
- 7.3.1.1 CONVENTIONAL DRUG DELIVERY FORMULATIONS 70
- 7.3.1.2 NOVEL DRUG DELIVERY FORMULATIONS 70
- 7.3.1.3 LONG ACTING INJECTION FORMULATIONS 70
- 7.3.2 INJECTABLE DRUG DELIVERY DEVICES 71
- 7.3.2.1 CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES 71
- 7.3.2.1.1 BY MATERIAL 71
- 7.3.2.1.1.1 GLASS 71
- 7.3.2.1.1.2 PLASTIC 72
- 7.3.2.1.2 BY PRODUCT TYPE 72
- 7.3.2.1.2.1 FILLABLE 72
- 7.3.2.1.2.2 PRE-FILLED 72
- 7.3.2.1.3 BY USABILITY 72
- 7.3.2.1.3.1 REUSABLE SYRINGES 72
- 7.3.2.1.3.2 DISPOSABLE SYRINGES 73
- 7.3.2.2 SELF INJECTION DRUG DELIVERY DEVICES 73
- 7.3.2.2.1 NEEDLE FREE INJECTORS 73
- 7.3.2.2.2 WEARABLE INJECTORS 73
- 7.3.2.2.3 PEN INJECTOR 73
- 7.3.2.2.4 AUTO INJECTORS 73
- 7.3.2.2.5 OTHERS 74
- 7.4 TOPICAL DRUG DELIVERY 75
- 7.4.1 TRANSDERMAL DRUG DELIVERY FORMULATIONS 75
- 7.4.1.1 SEMI-SOLID TOPICAL DRUG DELIVERY FORMULATIONS 76
- 7.4.1.1.1 OINTMENTS 76
- 7.4.1.1.2 CREAMS 76

- 7.4.1.1.3 LOTIONS 76
- 7.4.1.1.4 GELS 76
- 7.4.1.1.5 PASTES 76
- 7.4.1.2 LIQUID TOPICAL DRUG DELIVERY FORMULATIONS 77
- 7.4.1.2.1 SUSPENSIONS 77
- 7.4.1.2.2 SOLUTIONS 77
- 7.4.1.3 SOLID TOPICAL DRUG DELIVERY FORMULATIONS 77
- 7.4.1.3.1 POWDER 77
- 7.4.1.3.2 SUPPOSITORS 78
- 7.5 OPHTHALMIC DRUG DELIVERY 78
- 7.5.1 OCCULAR DRUG DELIVERY FORMULATIONS 79
- 7.5.1.1 LIQUID OCCULAR DRUG DELIVERY FORMULATIONS 79
- 7.5.1.1.1 SOLUTIONS 79
- 7.5.1.1.2 SUSPENSIONS 79
- 7.5.1.2 SEMI SOLID OCCULAR DRUG DELIVERY FORMULATIONS 80
- 7.5.1.2.1 GELS 80
- 7.5.1.2.2 OINTMENTS 80
- 7.5.2 OCCULAR DRUG DELIVERY DEVICES 80
- 7.6 NASAL DRUG DELIVERY 80
- 7.6.1 NASAL DROPS 81
- 7.6.2 NASAL SPRAYS 81
- 7.6.3 NASAL POWDERS 81
- 7.6.4 NASAL GELS 81
- 7.7 PULMONARY DRUG DELIVERY 81
- 7.7.1 METERED DOSE INHALERS (MDI) 82
- 7.7.2 DRY POWDER INHALERS (DPI) 82
- **7.7.3 NEBULIZERS 82**
- 7.7.3.1 JET NEBULIZERS 82
- 7.7.3.2 ULTRASONIC NEBULIZERS 83
- 7.7.3.3 SOFT MIST NEBULIZERS 83
- 7.8 TRANSMUCOSAL DRUG DELIVERY 83
- 7.8.1 ORAL TRANSMUCOSAL DRUG DELIVERY 84
- 7.8.1.1 BUCCAL DRUG DELIVERY 84
- 7.8.1.2 SUBLINGUAL DRUG DELIVERY 84
- 7.8.2 OTHER TRANSMUCOSAL DRUG DELIVERY 84
- 7.8.2.1 RECTAL TRANSMUCOSAL DRUG DELIVERY 84
- 7.8.2.2 VAGINAL TRANSMUCOSAL DRUG DELIVERY 85
- 7.9 IMPLANTABLE DRUG DELIVERY 85
- 7.9.1 PASSIVE IMPLANTABLE DRUG DELIVERY DEVICES 85
- 7.9.2 ACTIVE IMPLANTABLE DRUG DELIVERY DEVICES 85
- 8 MIDDLE EAST AND AFRICA DRUG DELIVERY DEVICES MARKET, BY END USER 86
- 8.1 OVERVIEW 87
- 8.2 HOSPITALS 90
- 8.3 HOME HEALTHCARE 90
- 8.4 CLINICS 91
- 8.5 COMMUNITY HEALTHCARE 91
- 8.6 OTHERS 92

- 9 MIDDLE EAST AND AFRICA DRUG DELIVERY DEVICES MARKET, BY DISTRIBUTION CHANNEL 93
- 9.1 OVERVIEW 94
- 9.2 DIRECT TENDERS 97
- 9.3 HOSPITAL PHARMACIES 97
- 9.4 PHARMACY STORES 98
- 9.5 ONLINE PHARMACY 98
- 10 MIDDLE EAST AND AFRICA DRUG DELIVERY DEVICES MARKET, BY REGION 99
- 10.1 MIDDLE EAST AND AFRICA 101
- 10.1.1 SOUTH AFRICA 109
- 10.1.2 SAUDI ARABIA 117
- 10.1.3 U.A.E. 125
- 10.1.4 EGYPT 133
- 10.1.5 ISRAEL 141
- 10.1.6 REST OF MIDDLE EAST AND AFRICA 149
- 11 MIDDLE EAST AND AFRICA DRUG DELIVERY DEVICES MARKET: COMPANY LANDSCAPE 150
- 11.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA
- 12 SWOT ANALYSIS 151
- 13 COMPANY PROFILE 152
- 13.1 JOHNSON & JOHNSON SERVICES, INC. 152
- 13.1.1 COMPANY SNAPSHOT 152
- 13.1.2 REVENUE ANALYSIS 152
- 13.1.3 COMPANY SHARE ANALYSIS 153
- 13.1.4 PRODUCT PORTFOLIO 153
- 13.1.5 RECENT DEVELOPMENTS 155
- 13.2 NOVARTIS AG 157
- 13.2.1 COMPANY SNAPSHOT 157
- 13.2.2 REVENUE ANALYSIS 157
- 13.2.3 COMPANY SHARE ANALYSIS 158
- 13.2.4 PRODUCT PORTFOLIO 158
- 13.2.5 RECENT DEVELOPMENTS 158
- 13.3 F. HOFFMANN-LA ROCHE LTD 160
- 13.3.1 COMPANY SNAPSHOT 160
- 13.3.2 REVENUE ANALYSIS 160
- 13.3.3 COMPANY SHARE ANALYSIS 161
- 13.3.4 PRODUCT PORTFOLIO 161
- 13.3.5 RECENT DEVELOPMENT 161
- 13.4 BAYER AG 162
- 13.4.1 COMPANY SNAPSHOT 162
- 13.4.2 REVENUE ANALYSIS 162
- 13.4.3 COMPANY SHARE ANALYSIS 163
- 13.4.4 PRODUCT PORTFOLIO 163
- 13.5 PFIZER INC. 164
- 13.5.1 COMPANY SNAPSHOT 164
- 13.5.2 REVENUE ANALYSIS 164
- 13.5.3 COMPANY SHARE ANALYSIS 165
- 13.5.4 PRODUCT PORTFOLIO 165
- 13.5.5 RECENT DEVELOPMENT 165

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 13.6 3M 166
- 13.6.1 COMPANY SNAPSHOT 166
- 13.6.2 REVENUE ANALYSIS 166
- 13.6.3 PRODUCT PORTFOLIO 167
- 13.6.4 RECENT DEVELOPMENTS 167
- 13.7 ABBVIE INC. 168
- 13.7.1 COMPANY SNAPSHOT 168
- 13.7.2 REVENUE ANALYSIS 169
- 13.7.3 PRODUCT PORTFOLIO 169
- 13.7.4 RECENT DEVELOPMENTS 170
- 13.8 AMGEN INC. 171
- 13.8.1 COMPANY SNAPSHOT 171
- 13.8.2 REVENUE ANALYSIS 171
- 13.8.3 PRODUCT PORTFOLIO 172
- 13.8.4 RECENT DEVELOPMENTS 173
- 13.9 BD 174
- 13.9.1 COMPANY SNAPSHOT 174
- 13.9.2 REVENUE ANALYSIS 174
- 13.9.3 PRODUCT PORTFOLIO 175
- 13.9.4 RECENT DEVELOPMENT 178
- 13.10 ELCAM MEDICAL 179
- 13.10.1 COMPANY SNAPSHOT 179
- 13.10.2 PRODUCT PORTFOLIO 179
- 13.10.3 RECENT DEVELOPMENT 180
- 13.11 ENABLE INJECTIONS 181
- 13.11.1 COMPANY SNAPSHOT 181
- 13.11.2 PRODUCT PORTFOLIO 181
- 13.11.3 RECENT DEVELOPMENTS 182
- 13.12 GERRESHEIMER AG 184
- 13.12.1 COMPANY SNAPSHOT 184
- 13.12.2 REVENUE ANALYSIS 184
- 13.12.3 PRODUCT PORTFOLIO 185
- 13.12.4 RECENT DEVELOPMENTS 188
- 13.13 GSK PLC. 190
- 13.13.1 COMPANY SNAPSHOT 190
- 13.13.2 REVENUE ANALYSIS 190
- 13.13.3 PRODUCT PORTFOLIO 191
- 13.13.4 RECENT DEVELOPMENTS 193
- 13.14 INSULET CORPORATION 195
- 13.14.1 COMPANY SNAPSHOT 195
- 13.14.2 REVENUE ANALYSIS 195
- 13.14.3 PRODUCT PORTFOLIO 196
- 13.14.4 RECENT DEVELOPMENTS 196
- 13.15 MEDMIX 197
- 13.15.1 COMPANY SNAPSHOT 197
- 13.15.2 REVENUE ANALYSIS 197
- 13.15.3 PRODUCT PORTFOLIO 198

- 13.15.4 RECENT DEVELOPMENTS 199
- 13.16 MERCK & CO., INC. 201
- 13.16.1 COMPANY SNAPSHOT 201
- 13.16.2 REVENUE ANALYSIS 201
- 13.16.3 PRODUCT PORTFOLIO 202
- 13.16.4 RECENT DEVELOPMENT 202
- 13.17 ORASURE TECHNOLOGIES INC. 203
- 13.17.1 COMPANY SNAPSHOT 203
- 13.17.2 REVENUE ANALYSIS 203
- 13.17.3 PRODUCT PORTFOLIO 204
- 13.17.4 RECENT DEVELOPMENT 204
- 13.18 SANOFI 205
- 13.18.1 COMPANY SNAPSHOT 205
- 13.18.2 REVENUE ANALYSIS 205
- 13.18.3 PRODUCT PORTFOLIO 206
- 13.18.4 RECENT DEVELOPMENTS 208
- 13.19 SMC LTD. 209
- 13.19.1 COMPANY SNAPSHOT 209
- 13.19.2 REVENUE ANALYSIS 209
- 13.19.3 PRODUCT PORTFOLIO 210
- 13.19.4 RECENT DEVELOPMENTS 210
- 13.20 VIVO SMART MEDICAL DEVICES LTD. 211
- 13.20.1 COMPANY SNAPSHOT 211
- 13.20.2 PRODUCT PORTFOLIO 211
- 13.20.3 RECENT DEVELOPMENT 211
- 13.21 WEST PHARMACEUTICAL SERVICES, INC. 212
- 13.21.1 COMPANY SNAPSHOT 212
- 13.21.2 REVENUE ANALYSIS 212
- 13.21.3 PRODUCT PORTFOLIO 213
- 13.21.4 RECENT DEVELOPMENT 213
- 14 QUESTIONNAIRE 214
- 15 RELATED REPORTS 217



Print this form

To place an Order with Scotts International:

Middle East and Africa Drug Delivery Devices Market

Market Report | 2024-08-01 | 217 pages | Data Bridge Market Research

| se License | | Price \$3500.00 |
|-------------------|--|--|
| | | \$3500.00 |
| icense | | Ψ3300.00 |
| | Corporate Users License | |
| | VAT | |
| | Total _ | |
| | | _ |
| Phone* | | |
| Last Name* | | |
| | | |
| EU Vat / Tax ID / | NIP number* | |
| City* | | |
| Country* | | |
| Date | 2025-05-13 | |
| | | |
| | Phone* Last Name* EU Vat / Tax ID / City* Country* | Last Name* EU Vat / Tax ID / NIP number* City* Country* |